

Contents

List of Contributors xvii

Preface xxiii

PART I

INTRODUCTION

1. Historical Perspectives on Mucosal Vaccines

MICHAEL W. RUSSELL AND PEARAY L. OGRA

- I. Introduction 3
- II. Existing Mucosal Vaccines 5
- III. Strategies for Enhancing Mucosal Vaccines 8
- IV. Oral Tolerance 12
- V. Concluding Remarks and Future Perspectives 13
- References 14

PART II

PRINCIPLES OF MUCOSAL VACCINE

2. Anatomical Uniqueness of the Mucosal Immune System (GALT, NALT, iBALT) for the Induction and Regulation of Mucosal Immunity and Tolerance

AARON SILVA-SANCHEZ AND TROY D. RANDALL

- I. Introduction 21
- II. Evolutionary Requirement for Mucosal Lymphoid Organs 22
- III. Gut-Associated Lymphoid Tissue 25
- IV. Development of Gut-Associated Lymphoid Tissue 32
- V. M Cell Differentiation in Gut-Associated Lymphoid Tissue 34

VI. Lymphoid Tissues of the Respiratory Tract 35

VII. Concluding Remarks 42

References 43

3. Mucosal Antigen Sampling Across the Villus Epithelium by Epithelial and Myeloid Cells

BRIAN L. KELSALL

- I. Introduction 55
- II. Basic Components of the Mucosal Barrier and Lymphoid Tissues 56
- III. Antigen Uptake Across the Villus Epithelium 58
- Acknowledgments 66
- References 66

4. Protective Activities of Mucosal Antibodies

JIRI MESTECKY

- I. Introduction 71
- II. Properties of Antibodies of Various Ig Isotypes in External Secretions 72
- III. Origin of Antibodies in External Secretions 73
- IV. Protective Effect of Mucosal Antibodies 73
- V. The Role of IgG in Mucosal Immunity 74
- VI. Mechanisms of Protection Mediated by Mucosal IgA Antibodies 75
- VII. Concluding Remarks 80
- References 80
- Further Reading 84

5. Mucosal Immunity for Inflammation: Regulation of Gut-Specific Lymphocyte Migration by Integrins

EUN JEONG PARK, EIJI KAWAMOTO AND MOTOMU SHIMAOKA

- I. Introduction 85
- II. Molecular Mechanisms for the Recruitment of Circulating Lymphocytes to Tissues 86

CONTENTS

- III. Integrin Deactivation as a Regulatory Mechanism for Efficient Cell Migration 87
- IV. Interstitial Migration 90
- V. Immunological Synapse 90
- VI. Imprinting of Homing Specificity by Dendritic Cells 91
- VII. Integrin $\alpha 4\beta 7$ -MAdCAM-1 Interactions 92
- VIII. Therapeutic Integrin Inhibition for Inflammatory Bowel Diseases 93
- IX. Iatrogenic and Genetic Immune-Deficiencies Involving Integrins 94
- X. Therapeutic Integrin Inhibition for HIV Infection 95
- References 96

6. Innate Immunity at Mucosal Surfaces

KOSUKE FUJIMOTO AND SATOSHI UEMATSU

- I. Introduction 101
- II. Innate Mucosal Barriers in the Gut 103
- III. Innate Immune Regulation in the Gut 106
- IV. Concluding Remarks 110
- References 110

7. Induction and Regulation of Mucosal Memory B Cell Responses

NILS LYCKE

- I. Introduction 117
- II. Mucosal Vaccine Induction of Memory B Cells 119
- III. The Inductive Site for Gut Memory B Cell Responses Is the Peyer's Patches 119
- IV. A Model System to Study Mucosal Memory B Cell Development 121
- V. The Germinal Center Reaction in Peripheral Lymph Nodes and Peyer's Patches 122
- VI. Respiratory Tract Infections and Mucosal Memory B Cells 122
- VII. Mucosal Memory B Cells and Homing Markers 123
- VIII. Are Mucosal Memory B Cells Sessile or Recirculating? 125
- IX. Memory B Cells Show Poor Clonal Relatedness to Long-Lived Plasma Cells Following Oral Priming Immunizations 127
- X. Considerations for Mucosal Subcomponent Vaccine Development 128

- XI. Concluding Remarks 128
- References 129

8. Induction and Regulation of Mucosal Memory T Cell Responses

KIYOSHI HIRAHARA AND TOSHINORI NAKAYAMA

- I. Introduction 133
- II. Mucosal Compartmentalization That Causes Inflammatory Responses in the Airway 133
- III. Mucosal Inflammation and Inducible Bronchus-Associated Lymphoid Tissue 136
- IV. Model of Disease Induction by T_H17 Cells 138
- V. Concluding Remarks 139
- Acknowledgments 139
- References 140

9. Influence of Commensal Microbiota and Metabolite for Mucosal Immunity

JILLIAN L. POPE, SARAH TOMKOVICH AND CHRISTIAN JOBIN

- I. Introduction 143
- II. Microbiota 144
- III. Mucosal Immunity 145
- IV. Skin Immunity 156
- V. Microbiota and Vaccines 157
- VI. Concluding Remarks 159
- Acknowledgment 159
- Financial Support 159
- References 160

PART III

MUCOSAL MODULATIONS FOR INDUCTION OF EFFECTIVE IMMUNITY

10. Innate Immunity-Based Mucosal Modulators and Adjuvants

BRANDI T. JOHNSON-WEAVER, SOMAN N. ABRAHAM AND HERMAN F. STAATS

- I. Introduction 167
- II. Innate Immune System Activators as Adjuvants for Mucosally Administered Subunit Vaccines 168

CONTENTS

- III. Cytokines as Mucosal Vaccine Adjuvants 168
- IV. Nanoemulsions as Mucosal Vaccine Adjuvants 171
- V. Mast-Cell-Activating Compounds With Adjuvant Activity 173
- VI. Cationic Polyethyleneimine Used as a Mucosal Vaccine Adjuvant 175
- VII. Mucosal Adjuvant Activity of Toll-Like Receptor Ligands 175
- VIII. Concluding Remarks and Future Perspective 178
- References 178

11. Toxin-Based Modulators for Regulation of Mucosal Immune Responses

EUNSOO KIM, ZAYED ATTIA, ESTELLE CORMET-BOYAKA AND PROSPER N. BOYAKA

- I. Introduction 185
- II. Toxins Used For Modulation of Immune Responses 185
- III. Toxin-Derivative Adjuvants for Mucosal Vaccines 187
- IV. Innate Mechanisms Regulated by Toxin-Based Adjuvants for Induction of Mucosal Immunity 191
- V. Induction of Tolerance by Toxin-Based Adjuvants 195
- VI. Concluding Remarks and Future Perspectives 195
- Acknowledgments 196
- References 196

12. Influence of Dietary Components and Commensal Bacteria on the Control of Mucosal Immunity

HIDEHIKO SUZUKI AND JUN KUNISAWA

- I. Introduction 203
- II. Vitamins 204
- III. Lipids 206
- IV. Commensal Bacteria and Their Metabolites 207
- V. Concluding Remarks 209
- Acknowledgment 209
- References 209

13. Mast Cells for the Control of Mucosal Immunity

HAE WOONG CHOI, BRANDI JOHNSON-WEAVER, HERMAN F. STAATS AND SOMAN N. ABRAHAM

- I. Introduction 213

- II. Exocytosis of Biologically Active Modulators 214
- III. Peripheral Location 215
- IV. Multipronged Activation at Infection Sites 216
- V. Initiation of Local Innate Immune Responses 217
- VI. Contributions to Adaptive Immune Responses 220
- VII. Dysregulated or Impaired Mast Cell Activity During Infection 222
- VIII. Concluding Remarks and Future Perspectives 223
- Acknowledgements 223
- References 223

14. Innate Lymphoid Cells for the Control of Mucosal Immunity

RANDY S. LONGMAN, MAEVA METZ AND DAVID ARTIS

- I. Introduction 229
- II. Innate Lymphoid Cell Development and Tissue Heterogeneity 229
- III. Organizing and Initiating Innate Lymphoid Cell-Dependent Barrier Immunity 232
- IV. Mucosal Innate Lymphoid Cells in Pathogen Defense 235
- V. Innate Lymphoid Cells in Mucosal Tissue Repair 237
- VI. Innate Lymphoid Cells in Allergy, Autoimmunity, and Persistent Inflammation 237
- VII. Cross-Regulation of Innate and Adaptive Immunity by Mucosal Innate Lymphoid Cells 238
- VIII. Concluding Remarks 239
- References 240

15. Mucosal Regulatory System for Balanced Immunity in the Gut

HISAKO KAYAMA AND KIYOSHI TAKEDA

- I. Introduction 247
- II. Induction of Intestinal Immune Tolerance by CD103⁺ Dendritic Cells 249
- III. Regulation of Immune Homeostasis by Intestinal Resident CX₃CR1^{high} Macrophages 250
- IV. Roles of Human Intestinal Myeloid Cells in the Maintenance of Gut Homeostasis and Inflammatory Bowel Disease 251
- V. Concluding Remarks 252
- Acknowledgments 252
- References 252

CONTENTS

16. Regulation of Mucosal Immunity
in the Genital Tract: Balancing Reproduction
and Protective Immunity

DANICA K. HICKEY, PETER MULVEY,
EMILY R. BRYAN, LOGAN TRIM AND KENNETH W. BEAGLEY

- I. Introduction 255
- II. Immunology of the Female Genital Tract 256
- III. Immunology of the Male Reproductive
Tract 264
- IV. Chlamydia 267
- V. *Chlamydia* as a Gastrointestinal Commensal: The
Elephant in the Room? 273
- VI. Genital Herpes 273
- VII. Concluding Remarks and Future
Perspectives 284
- Key Points 286
- References 286

17. Mucosal Regulatory System
for Balanced Ocular Immunity

DEREK J. ROYER, MICAELA L. MONTGOMERY AND
DANIEL J.J. CARR

- I. Introduction 299
- II. Organization of the Ocular Surface Mucosa 300
- III. Immunology of the Ocular Surface Mucosa 301
- IV. Targets and Strategies for Vaccine
Development 303
- References 307
- Further Reading 312

18. Mucosal Regulatory System
for the Balanced Immunity in the Middle Ear
and Nasopharynx

HIDEYUKI KAWAUCHI

- I. Introduction 313
- II. Innate and Acquired Immunity of Middle Ear and
Nasopharynx 314
- III. Immunomodulation of Middle Ear and
Nasopharyngeal Mucosae and Its Clinical
Impact 316
- IV. Innovative Immunotherapy for Attenuating Nasal
Symptoms of Cedar Pollinosis via the Mucosal Route
With Transgenic Rice Seeds Containing
Hypoallergenic Cryj1 and Cryj2 T Cell
Epitopes 317

- V. Concluding Remarks and Future
Perspectives 319
- References 320

PART IV

CURRENT AND NEW
APPROACHES FOR MUCOSAL
VACCINE DELIVERY

19. Current and New Approaches for Mucosal
Vaccine Delivery

JOON HAENG RHEE

- I. Introduction 325
- II. Nano/Microscale Carriers as Promising Delivery
Tools for Vaccines 326
- III. Mucosal Vaccine Delivery: Past, Present and
Future 333
- IV. Liposomes 337
- V. Immunostimulating Complexes 337
- VI. Virus-Like Particles 338
- VII. Polymeric Particle-Based Oral Delivery 338
- VIII. Oral Delivery of Vaccines Using Food
Materials 340
- IX. Liposomes 344
- X. Chitosan 344
- XI. Starch Nanoparticles 345
- XII. Polymer Nanoparticles 345
- XIII. Nanogels 346
- XIV. Concluding Remarks and Future Perspectives 346
- References 346
- Further Reading 356

20. Plant-Based Mucosal Vaccine
Delivery Systems

TATSUHIKO AZEGAMI, YOSHIKAZU YUKI AND
HIROSHI KIYONO

- I. Introduction 357
- II. Transgenic Technologies for Vaccine Production in
Plants 359
- III. Plant-Based Vaccines for the Prevention and Control
of Infectious Diseases 361
- IV. Concluding Remarks 367
- References 367

CONTENTS

21. Plant-Based Mucosal Immunotherapy: Challenges for Commercialization

KENNETH L. BOST AND KENNETH J. PILLER

- I. Introduction 371
 - II. Advances in Developing Plant-Based Mucosal Immunotherapy Products: A Quarter of a Century Later 372
 - III. A Lack of Recent Human Clinical Trials Testing the Safety and/or Efficacy of Plant-Based Mucosal Immunotherapy 372
 - IV. Cost of Production for Plant-Based Mucosal Immunotherapeutics: Is This a Realistic Advantage? 373
 - V. Infrastructure and Protocols for Plant-Based Mucosal Immunotherapeutic Manufacturing 374
 - VI. Regulatory Approval for Plant-Based Mucosal Immunotherapy 375
 - VII. Safety of Plant-Made Biologics and Plant-Specific Glycosylation 375
 - VIII. Mucosal Tolerance Therapy Using Plant-Made Proteins 376
 - IX. Global Contamination From Food-Crop-Made Vaccines or Tolerogens 377
 - X. Safety of Consumable Formulations From Food-Crop-Made Vaccines or Tolerogens 378
 - XI. Separating Expression From Finishing the Product Geographically and Over Extended Periods of Time Using Seed-Based Platforms 378
 - XII. Plant-Based Mucosal Immunotherapy: Challenges for Commercialization 379
- References 380

22. Attenuated *Salmonella* for Oral Immunization

KENNETH L. ROLAND, QINGKE KONG AND YANLONG JIANG

- I. Introduction 383
 - II. Approaches for Attenuation 384
 - III. Vaccines against nontyphoidal *Salmonella* 395
 - IV. Concluding remarks 395
- References 395

23. Recombinant *Bacillus Calmette-Guérin* for Mucosal Immunity

STEVEN C. DERRICK

- I. Introduction 401
- II. Oral Immunization 402

- III. Intravesical Immunotherapy 407
 - IV. Stimulation of Pulmonary Immune Responses 409
- References 415
Further Reading 417

24. Recombinant Adenovirus Vectors as Mucosal Vaccines

KRISTEL L. EMMER AND HILDEGUND C.J. ERTL

- I. Introduction 419
 - II. Adenoviruses 420
 - III. Immune Responses to Adenoviruses 420
 - IV. Types of Adenovirus Vectors 422
 - V. Construction, Purification, and Titration of Adenovirus Vectors 423
 - VI. Quality Control of Adenovirus Vectors 423
 - VII. Thermostability of Adenovirus Vectors 424
 - VIII. Immunogenicity of Adenovirus Vectors 424
 - IX. The Mucosal Immune System 424
 - X. Mucosal Vaccines 425
 - XI. Adenovirus Vectors as Oral Vaccines 426
 - XII. Adenovirus Vectors as Intranasal Vaccines 430
 - XIII. Immunizations Through the Rectal or Genital Mucosa 436
 - XIV. Use of Adjuvants for Mucosal Adenovirus Vector Vaccines 436
 - XV. Concluding Remarks and Future Perspectives 436
- References 437

25. Mucosal Approaches for Systemic Immunity to Anthrax, Brucellosis, and Plague

DAVID W. PASCUAL

- I. Introduction 445
 - II. Origins of Vaccination 446
 - III. Anthrax 446
 - IV. Brucellosis 448
 - V. Plague 451
- Acknowledgment 454
References 454

26. Nanodelivery Vehicles for Mucosal Vaccines

RIKA NAKAHASHI-OUCHIDA, YOSHIKAZU YUKI AND HIROSHI KIYONO

- I. Introduction 461
- II. Characteristics of the Nasal Immune System 462
- III. Drug-Delivery Systems for Nasal Vaccines 464

CONTENTS

- IV. cCHP Nanogel as a Drug-Delivery System for Nasal Vaccines 467
- V. Development of a Nanogel-Based Nasal Vaccine Against Pneumonia 467
- VI. Application of cCHP Nasal Vaccines Against Noninfectious Diseases 471
- VII. Concluding Remarks and Future Perspectives 471
- Abbreviations 472
- References 472

27. Effectiveness of Sublingual Immunization: Innovation for Preventing Infectious Diseases

MI-NA KWEON

- I. Introduction 477
- II. Localization of Antigen-Presenting Cells in the Sublingual Mucosa 478
- III. Role of Draining Lymph Nodes in Sublingual Vaccination 479
- IV. Mechanism for Induction of CD4⁺ T Cell Activation Following Sublingual Vaccination 479
- V. Sublingual Vaccination Induces Both Systemic and Mucosal Antibody Responses 481
- VI. Sublingual Administration Is Useful for Induction of Antibody Against Viral Infection 481
- VII. Sublingual Administration Does Not Redirect Antigens to the Central Nervous System 482
- VIII. Sublingual Vaccination Induces T and B Cell Activation in Female Mouse Genital Tissues 482
- IX. Concluding Remarks and Future Perspectives 482
- References 484

28. M Cell-Targeted Vaccines

SHINTARO SATO AND DAVID W. PASCUAL

- I. Introduction 487
- II. M Cell Differentiation 488
- III. Candidate Molecules for M Cell Targeting and Their Ligands 490
- IV. Contribution of M Cells for the Development of Oral Tolerance 493
- V. Enhancement of M Cell Number and Function 494
- VI. Concluding Remarks and Future Perspectives 495
- References 495

PART V

MUCOSAL VACCINES FOR BACTERIAL DISEASES

29. Induction of Local and Systemic Immunity by *Salmonella* Typhi in Humans

FRANKLIN R. TOAPANTA, JAYAUM S. BOOTH AND MARCELO B. SZTEIN

- I. Introduction 501
- II. Current Vaccines and Models to Study Immunogenicity to *Salmonella* Typhi 501
- III. Live Attenuated Oral Vaccine and Human Challenge Model of Typhoid Fever 502
- IV. Systemic T Cell Immunity Induced by Oral *Salmonella* Typhi 503
- V. Humoral and Systemic B Cell Immunity Induced by Oral *Salmonella* Typhi 503
- VI. Changes in Innate and Mucosal-Associate Invariant T Cells Induced by Oral *Salmonella* Typhi 504
- VII. Gut-Homing Memory T Cells: A Window Into Mucosal Immunity 505
- VIII. Accumulation and Retention of Gut-Homing Memory T Cells in the Mucosa 506
- IX. Mucosal Immunity to *Salmonella* Typhi 508
- X. Relationship Between Systemic and Mucosal Immunity to *Salmonella* Typhi 509
- XI. Concluding Remarks 509
- Acknowledgment 510
- References 510

30. Oral *Shigella* Vaccines

MARCELA F. PASETTI, MALABI M. VENKATESAN AND EILEEN M. BARRY

- I. Introduction 515
- II. *Shigella* Infection: Burden of Disease and Vulnerable Groups 516
- III. *Shigella* Pathogenesis and Virulence Factors 517
- IV. Naturally Acquired Immunity Against *Shigella* 518
- V. Immune Responses to *Shigella* in Children 519
- VI. Animal Models of Mucosal *Shigella* Infection 520
- VII. History of Oral *Shigella* Vaccine Candidates 520
- VIII. Immunity Induced by Oral *Shigella* Vaccines 521
- IX. Multivalent Oral *Shigella* Vaccines 525

CONTENTS

- X. Parenteral *Shigella* Vaccine Candidates 526
XI. An Ideal Oral *Shigella* Vaccine: Features and Implementation 528
XII. Concluding Remarks 528
Acknowledgments 529
References 529
31. Cholera Immunity and Development and Use of Oral Cholera Vaccines for Disease Control
FIRDAUSI QADRI, JOHN D. CLEMENS AND JAN HOLMGREN
- I. Introduction 537
II. Susceptibility and Innate Immunity in Cholera 538
III. Oral Cholera Vaccines 540
IV. Adaptive Mucosal Immune Responses in Cholera 542
V. Systemic Antibody and Memory B Cell Responses 548
VI. Modifiers of Immune Responses 551
VII. Public Health Use of Oral Cholera Vaccines 553
VIII. WHO Recommendations and a "Global RoadMap to End Cholera by 2030" 554
IX. Concluding Remarks and Future Perspectives 555
References 556
32. Oral Vaccines for Enterotoxigenic *Escherichia coli*
NILS CARLIN AND ANN-MARI SVENNERHOLM
- I. Introduction 563
II. Enterotoxigenic *Escherichia coli* Vaccine Candidates 564
III. Evaluation of Optimal Administration Routes of an Enterotoxigenic *Escherichia coli* Vaccine 565
IV. Oral Mucosal Adjuvants 569
V. Methods for Assessing Mucosal Immune Responses Against Enterotoxigenic *Escherichia coli* Candidate Vaccines in Humans 569
VI. Candidate Vaccines in Clinical Development 570
VII. Concluding Remarks 573
References 574
33. A Future for a Vaccine Against the Cancer-Inducing Bacterium *Helicobacter pylori*?
THOMAS F. MEYER AND PAU MOREY
- I. Introduction 579
II. The Therapeutic Tool Box of *Helicobacter pylori* Infections 580
III. The Unheeded Role of Epithelial Cells in the Execution of Mucosal Defense 581
IV. Vaccines as Stimulators of Mucosal Immunity 583
V. Natural Immunity Against *Helicobacter pylori* 585
VI. The Failure of Past Vaccination Attempts 586
VII. Unmasking *Helicobacter pylori*'s Immune Evasion Strategy 587
VIII. Concluding Remarks and Future Perspectives 590
References 591
34. Mucosal Vaccines for *Streptococcus pneumoniae*
EDWIN SWIATLO AND LARRY S. MCDANIEL
- I. Introduction 597
II. Host Immune Responses to Pneumococci During Nasopharyngeal Colonization 600
III. Immunization Against *Streptococcus pneumoniae* at Mucosal Surfaces 603
IV. Current and Future Status of Human Mucosal Vaccine Trials 606
V. Concluding Remarks 606
Acknowledgment 607
References 607
35. Development of a Mucosal TB Vaccine Using Human Parainfluenza Type 2 Virus
YUSUKE TSUJIMURA AND YASUHIRO YASUTOMI
- I. Introduction 611
II. Mucosal Immune Responses in TB Infection 613
III. Vaccine Delivery Systems for Induction of Mucosal Immunity 615
IV. Novel Vaccine Candidate, rHPIV2, in TB Protection 616
V. Protective Effects of an rHPIV2 Vaccine in Mice With TB 617
VI. Possibilities of rHPIV2 as a Next-Generation Vaccine Candidate 618
VII. Future Study Using the HPIV2 Vaccine 620
Abbreviations 620
References 621

CONTENTS

36. Sexually Transmitted Infections and the Urgent Need for Vaccines: A Review of Four Major Bacterial STI Pathogens

AVINASH KOLLIPARA, DE'ASHIA LEE AND TONI DARVILLE

- I. Introduction 625
- II. Chlamydia 626
- III. Gonorrhea 632
- IV. Syphilis 635
- V. Mycoplasma 638
- VI. Concluding Remarks 639
- References 641

37. Mucosal Vaccines for Oral Disease

TOMOKO KURITA-OCHIAI,
TOMOMI HASHIZUME-TAKIZAWA, RYOKI KOBAYASHI
AND MASAFUMI YAMAMOTO

- I. Introduction 649
- II. Mucosal Vaccines for Caries Prevention 650
- III. Mucosal Vaccines for Periodontal Disease 652
- IV. Protein Based Mucosal Vaccine 652
- V. DNA-Based Vaccine 653
- VI. Nasal Administration of Periodontal Vaccine 654
- VII. Sublingual Vaccine for Periodontal Diseases 655
- VIII. Concluding Remarks 656
- Acknowledgment 657
- References 657

PART VI

MUCOSAL VACCINES FOR VIRAL DISEASES

38. Vaccination Against Respiratory Syncytial Virus

TRACY J. RUCKWARDT, MICHELLE C. CRANK,
KAITLYN M. MORABITO AND BARNEY S. GRAHAM

- I. Introduction 665
- II. Global Impact and Clinical Disease 666
- III. Correlates of Protection 667
- IV. Maternal Immunization to Protect Vulnerable Infants 669
- V. RSV Immunity and Vaccination in Infants and Young Children 670
- VI. RSV Immunity and Vaccination in Older Adults 672

- VII. Concluding Remarks 672
- References 673

39. Nasal Influenza Vaccines

HIDEKI HASEGAWA

- I. Introduction 677
- II. Humoral Immune Responses to Influenza Virus Infection 677
- III. Development of the Nasal Influenza Vaccines 678
- References 681

40. The Role of Innate Immunity in Regulating Rotavirus Replication, Pathogenesis, and Host Range Restriction and the Implications for Live Rotaviral Vaccine Development

ADRISH SEN, SIYUAN DING AND HARRY B. GREENBERG

- I. Introduction 683
- II. Host Innate Immune Sensors and Rotavirus Infection 683
- III. Host Innate Responses to Rotavirus and Their Effects on Viral Replication 686
- IV. Regulation of the Interferon Induction Pathway by Rotavirus 687
- V. Taking Advantage of Rotavirus Host Range Restriction to Reliably Attenuate Live Rotavirus Vaccine Candidates 692
- References 695

41. Development of Oral Rotavirus and Norovirus Vaccines

ADAM HUYS, KATRINA R. GRAU AND STEPHANIE M. KARST

- I. Introduction 699
- II. Rotavirus Vaccine Development 699
- III. Norovirus Vaccine Development 704
- IV. Concluding Remarks 707
- References 707

42. Mucosal Vaccines Against HIV/SIV Infection

HIROYUKI YAMAMOTO, HIROSHI ISHII AND
TETSURO MATANO

- I. Introduction 713
- II. Mucosal Vaccines Inducing HIV-Specific Antibody Responses 713

CONTENTS

- III. Mucosal Vaccines Inducing HIV-Specific T Cell Responses 716
- References 719

43. Mucosal Vaccines for Genital Herpes

JIEUN OH AND AKIKO IWASAKI

- I. Introduction 723
- II. HSV-1 and HSV-2 Virus Life Cycle 724
- III. Pathogenesis of Genital Herpes 725
- IV. Symptoms of Genital Herpes 726
- V. Immune Protective Mechanisms Against HSV Infections 726
- VI. Vaccine Approaches Against Genital Herpes 729
- VII. Future Strategies for HSV-2 Vaccine 731
- VIII. Concluding Remarks and Future Perspectives 732
- Acknowledgment 732
- References 732

44. Maternal Vaccination for Protection Against Maternal and Infant Bacterial and Viral Pathogens

DAVID R. MARTINEZ, JESSE MANGOLD AND SALLIE R. PERMAR

- I. Introduction 735
- II. Diphtheria, Pertussis, and Tetanus 736
- III. Influenza Virus 737
- IV. Measles, Mumps, and Rubella 738
- V. The Next Frontier of Maternal Vaccines 739
- VI. Concluding Remarks 744
- VII. Summary of Key Points 745
- Acknowledgment 745
- Funding 745
- References 745

PART VII

NEW AND NOVEL APPROACHES FOR MUCOSAL VACCINE DEVELOPMENT

45. Systems Biological Approaches for Mucosal Vaccine Development

BALI PULENDRAN

- I. Introduction 753

- II. Systems Vaccinology 756
- III. Systems Biology of Vaccines Against Mucosal Infections 762
- IV. Concluding Remarks 768
- Acknowledgments 769
- References 769

46. Harnessing $\gamma\delta$ T Cells as Natural Immune Modulators

JODI F. HEDGES AND MARK A. JUTILA

- I. Introduction 773
- II. $\gamma\delta$ T Cell Surface Receptors 774
- III. Similarities of $\gamma\delta$ T Cells to Myeloid and Macrophage Cells 775
- IV. $\gamma\delta$ T Cell-Mediated Cytotoxicity 775
- V. $\gamma\delta$ T Cell Cytokine Production 776
- VI. Role of $\gamma\delta$ T Cells in Infectious Diseases 776
- VII. Therapeutic Potential for Manipulation of $\gamma\delta$ T Cells 777
- VIII. Plant Polyphenols for the Activation of $\gamma\delta$ T Cells 778
- IX. Concluding Remarks 782
- Acknowledgments 782
- Abbreviations 782
- References 782

47. Mucosal Vaccines for Aged: Challenges and Struggles in Immunosenescence

KOHTARO FUJIIHASHI

- I. Introduction 789
- II. Age-Associated Changes in the Gastrointestinal Tract Immune System 791
- III. Potential Mechanisms in Gut Aging: Roles of M Cells 793
- IV. Involvement of Mucosal CD4⁺ T Cells in Gut Aging 793
- V. The Intestinal Microbiota Potentially Shapes Mucosal Immunosenescence 794
- VI. Rejuvenation of Gut Immunity by Mesenchymal Stem Cell Transfer 795
- VII. Nasopharyngeal-Associated Lymphoid Tissue Versus Gut-Associated Lymphoid Tissue: Similarities and Gaps 796
- VIII. Distinct Aging Process of Nasopharyngeal-Associated Lymphoid Tissue Function 797

CONTENTS

- IX. Mucosal Vaccines and Therapies Fight for Immunosenescence 799
- X. A Dendritic Cell-Targeting Mucosal Vaccines for Aged 800
- XI. Next Generation of Potent Mucosal Vaccines for the Elderly 802
- Acknowledgment 802
- References 803

PART VIII

CAN MUCOSAL VACCINES BE APPLIED TO OTHER INFECTIOUS AND NONINFECTIOUS DISEASES?

48. Mucosal Vaccine Development for Veterinary and Aquatic Diseases

HEATHER L. WILSON, VOLKER GERDTS AND LORNE A. BABIUK

- I. Introduction 811
- II. Exploration of Commercial and Experimental Mucosal Veterinary Vaccines 813
- III. Veterinary Vaccines and One Health 825
- IV. Concluding Remarks 826
- References 826

49. Mucosal Vaccine for Malaria

MICHELLE SUE JANN LEE AND CEVAYIR COBAN

- I. Introduction 831
- II. Malaria's Effect on the Gastrointestinal System 832
- III. Gastrointestinal system's effect on malaria: a role for gut microbiota? 833
- IV. Mucosal Vaccines Against Malaria 835
- V. Concluding Remarks 836
- Acknowledgments 837
- References 837

50. Mucosal Vaccine for Parasitic Infections

HIROTOMO KATO

- I. Introduction 841
- II. Protozoan Infections 842
- III. Helminth Infections 846
- IV. Concluding Remarks 849
- References 849

51. Mucosal Vaccines for Allergy and Tolerance

ANDREA M. KEMTER AND CATHRYN R. NAGLER

- I. Introduction 855
- II. Immunotherapy 856
- III. Microbiota 862
- IV. Concluding Remarks 863
- References 863

52. Novel Strategies for Targeting the Control of Mucosal Inflammation

PETER B. ERNST, IOANNIS DRYGIANNAKIS AND HIUTUNG CHU

- I. Introduction 869
- II. For Every Action, There Is an Equal and Opposite Reaction 869
- III. Key Features of the Host Response in Homeostasis 871
- IV. Microbial Communities, Microbial Pathogenesis, and Dysbiosis 871
- V. The Concept of a Homeostatic Scar and Immunological Dysfunction 872
- VI. The Impact of Immunization on Homeostasis 873
- VII. Future Perspectives 876
- VIII. Concluding Remarks 876
- Acknowledgments 876
- References 877

Index 881